Pulse Biosciences, Inc.
NASDAQ:PLSEMedical - Instruments & Supplies
+$0.97 today
- Market cap
- $3.37B
- Beta
- 1.66
- P/E (TTM)
- -24.0
- EPS (TTM)
- -$1.10
Volume 0.33M
Average 0.31M
PLSE Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Pulse Biosciences, Inc.NASDAQ: PLSE
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue grows, but more slowly than its trailing trend
Q2 FY2026 cost of revenue of $273K rose 2.2% year over year, behind the +439.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 26.2% from the prior quarter. Over 3 fiscal years it compounded at -48.7% a year.
Context
- Cost of revenue amounted to 460.0% of revenue in FY2025.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +439.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.61M USD
- Year-over-year change
- —
- 4-year CAGR
- -4.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.61M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 1.21M | -89.9% |
| FY2022 | 2022-12-31 | 11.94M | +506.9% |
| FY2021 | 2021-12-31 | 1.97M | — |
Cost of Revenue vs competitors
How PLSE compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +439.7% is the highest of 10, against a peer median of -5.7%.
- Cost of revenue amounts to 121.6% of revenue for PLSE, versus a peer median of 18.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $449.04M USD | -8.4% | -12.5% | 77.3% | |
| LTM Mar 2026 | $167.29M USD | +17.8% | +13.3% | 24.8% | |
| LTM Apr 2026 | $68.44M USD | -5.7% | -2.2% | 23.6% | |
| LTM Mar 2026 | $47.24M USD | +46.8% | — | 42.8% | |
| LTM Jan 2026 | $42.91M USD | +23.8% | — | 51.2% | |
| LTM Mar 2026 | $30.96M USD | +10.1% | +28.2% | 14.1% | |
| LTM Jun 2026 | $1.44M USD | +439.7% | -48.7% | 121.6% | |
| LTM Jun 2026 | $615K USD | -96.7% | +82.0% | 13.7% | |
| LTM Jun 2026 | $347K USD | -97.2% | — | 0.6% | |
| LTM Jun 2026 | $76K USD | — | — | 4.0% | |
| LTM Mar 2026 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding PLSE) | — | -5.7% | +13.3% | 18.8% | |
Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.42M | 700K | 0 | 0 | 350K |
| Cost of Revenue | 1.97M | 11.94M | 1.21M | 0 | 1.61M |
| Gross Profit | (550K) | (11.24M) | (1.21M) | 0 | (1.26M) |
| Gross Margin | -38.8% | -1606.3% | — | — | -360.0% |
| Research & Development | 28.64M | 20.84M | 27.8M | 32.34M | 44.72M |
| Selling, General & Admin | 33.82M | 25.97M | 15.78M | 23.92M | 32.03M |
| Operating Expenses | 62.46M | 46.81M | 42.37M | 56.26M | 75.68M |
| Depreciation & Amortization | 1.15M | 1.36M | 1.21M | 1.18M | 1.07M |
| EBITDA | (62.51M) | (57.15M) | (39.9M) | (52.41M) | (71.71M) |
| EBITDA Margin | -4408.6% | -8164.3% | — | — | -20488.6% |
| Operating Income | (63.01M) | (58.06M) | (43.57M) | (56.26M) | (76.94M) |
| Operating Margin | -4443.9% | -8293.9% | — | — | -21982.6% |
| Interest Income | 0 | 0 | 2.46M | 2.67M | 4.21M |
| Interest Expense | 646K | 448K | 1.1M | 0 | 0 |
| Other Income / Expenses | (646K) | (448K) | 1.36M | 2.67M | 4.16M |
| Income Before Tax | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Pre-Tax Margin | -4489.4% | -8357.9% | — | — | -20794.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Net Margin | -4489.4% | -8357.9% | — | — | -20794.6% |
| EPS (Basic) | (2.28) | (1.72) | (0.88) | (0.92) | (1.08) |
| EPS (Diluted) | (2.28) | (1.72) | (0.88) | (0.92) | (1.08) |
| Weighted Avg Shares | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M |
| Weighted Avg Shares (Diluted) | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M |
Pulse Biosciences, Inc.
NASDAQ:PLSE
Intrinsic Alpha fair value
Locked
Current Price
$45.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.